PP-089 A new ultra short regimen with dexlansoprazole, moxifloxacin, amoxicillin, nitazoxanide, and doxycycline (DeMAND) in eradication of Helicobacter pylori: an open-label randomized clinical trial
Abstract
PP-088 Association of Helicobacter pylori infection with gastroduodenal diseases in Nepal J.L. Pathak1 *, Y.P. Deo2, P. Deo1, S. Raj Kadel3. 1Department of Clinical Test and Diagnostics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China, 2Department of Clinical Pathology, Om Hospital and Research Center, Kathmandu, Nepal, 3Department of Clinical Medicine, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.